Johnson & Johnson single-dose vaccine offers good defense against Covid, major study finds
Published On:February 01, 2021
According to the company's phase 3 trial results, the one-shot vaccine developed by Janssen, of Johnson & Johnson, has been shown to generate high levels of coronavirus safety. The jab was 66 per cent successful in preventing mild to serious cases of Covid-19 in a global study of more than 44,000 participants. Among those volunteers who had received the vaccine, there were no cases of hospitalization or death," the US firm said." This efficacy rate falls short of the safety caused by the vaccine rivals of Johnson & Johnson-BioNTech/Pfizer, Moderna and Oxford/AstraZeneca-but the single-dose strategy would make it an enticing choice for governments scrambling to inoculate their populations in the face of increasing worldwide cases. "This is a single shot that can be easily given, it completely protects us from what we fear, having to go to the emergency room or a hospital," explained Mathai Mammen, J&J's pharmaceutical division's head of global research and development. "It will alter the nature of the disease." Around 30 million doses of the vaccine have been pre-ordered by the United Kingdom, and the news comes after Novavax announced that their own two-shot jab was 89 percent successful. "The health secretary, Matt Hancock, tweeted on Friday, "This is even more positive news from Janssen on vaccinations.
Are you looking for a Market Research Reports? Just contact our consultant.